Hemolytic Disease of the Newborn (HDN)

Shivani V. Mohite, Dhanushree M. Gosavi, Rutuja S. Devkar, Ravi P. Barkade

Abstract: **- Hemolytic disease of the Newborn (HDN), also known as Erythroblastosis fetalis, is a hemolytic condition that generally affects rhesus-positive fetuses and babies born to rhesus-negative mothers. The pathophysiology of HDN begins with motherly antibodies attacking fetal red blood cells following alloimmunization due to rhesus or ABO incompatibility between the motherly and fetal blood. Preliminarily, HDN was known to cause death in 1 of all pregnancies, but with the arrival of immunoprophylactic therapies condition can be presently fairly well managed with smaller complications if diagnosed beforehand. To help the disease, before intravenous immunoglobulin (IVIG) should be given to pregnant Rh- women who haven't sensitized. The diagnosis and management of pregnant women with HDN is premised on laboratory and radiographic monitoring. This review covers the disorder's etiology, pathophysiology, and administration, as well as treatment and their management to help in unborn investigation and confirmation-based medical practice.**

Keywords: **ALLOIMMUNIZATION, HAEMOLYSIS, IMMUNOPROPHYLAXIS**.

INTRODUCTION

Hemolytic disorder of the Newborn (HDN), also known as Erythroblastosis fetalis, is a hemolytic condition that generally affects rhesus-positive fetuses and babies born to rhesus-negative mothers [1]. The most common cause of HDN is ABO incompatibility, in which cases the haemolysis is generally mild. More severe cases of HDN can be caused by anti-D, anti-C and anti-K. Anti-K suppresses neonatal red cell production as the K antigen is one of the first antigens to be expressed on the red cells during red cell production [2].

During pregnancy, motherly antibodies are transported across the placenta and enter the fetal distribution and attack the red blood cells in the fetal distribution; the red cells are broken down and the fetus can develop reticulocytosis, hyperbilirubinemia and anemia [3]. Preliminarily, HDN was known to produce fetal death in one percent of all pregnancies, but with the arrival of immunoprophylactic remedies, the condition can be presently fairly well managed with smaller complications if diagnosed beforehand [1]. Through early discovery, administration, and prevention of this disease, the appearance, and prevalence of HDFN have exponentially reduced in the once 50 years [4].

The first pregnancies generally aren't affected. Women generally develop anti-Rh-D antibodies after delivery or loss of an Rh D-positive neonate, placing their posterior pregnancies at trouble for transplacental antibody transfer and disease. The anti-Rh D antibodies are generally of IgG or IgG isotypes, and IgG is more pathogenic to the fetus than IgG [2]

HDN has been estimated to affect 3 to 8 for every 1 00,000 cases yearly. Before developing anti-D prophylaxis, it was responsible for fetal loss in 1 of all pregnancies. The circumstance of HDN is directly identified with the inheritance pattern in women that results in antibody isotype switching, cross the placenta and enter the fetal circulation or through (fetomaternal hemorrhage) FMH [1]



Fig.1 Hemolytic Disease of Newborn.

Causes: -

During pregnancy, RBCs from the coming baby can cross into the mother's blood through the placenta. HDN occurs when the immune system of the mother sees a baby's RBCs as foreign. Antibodies also develop against the baby's RBCs. These antibodies attack the RBCs in the baby's blood and make them to break down too prematurely [5]. Generally, the cross-over occurs through the placenta during

gestation or delivery. This leads to severe complications in the baby's system, which may indeed lead to the ultimate demise of the baby. still, the immune system of the mother doesn't get relieve of the antibodies. Still, it develops immunological memory, which can generate the secretion of further antibodies upon re-exposure to the antigen. As a result, HDN is likely to come in the alternate and the posterior pregnancies, indeed after a contraction or abortion [6].

Epidemiology: -

Hemolytic disorder of the fetus and infant was first described by Dr. Louis K. Diamond in 1932 when he wrote about erythroblastosis fetalis in the infant grounded on supplemental smears [7]. Rhesus D-negative (RhD) immunoprophylaxis was first introduced in 1968, which dropped the occurrence of HDFN from 1 of all infants worldwide (with 50 mortality) to 0.5 [4]. The occurrence of HDFN dropped truly further to 0.1 with the administration of antepartum RhD immunoprophylaxis [8]. still, despite acceptable RhD immunoprophylaxis, an estimated 1 to 3 in 1000 Rh-negative women still develop alloimmunization moment. therefore, it's important to stay watchful for the development of HDFN [4]. There are an estimated 3/100 000 to 80/100000 cases of HDFN per time in the United States [9]. The motherly blood group antibodies that induce HDFN can be naturally coming ABO antibodies (isohemagglutinins) or develop after exposure to foreign RBC; the ultimate is called blood group alloantibodies. For HDFN to do, the fetus must be antigen positive (paternally inherited), and the mother must be antigen negative. Several studies have researched the frequencies of red cell sensitization. In a large series of 22 102 women in the US, 254 (1.15) of the women were set up to have a red cell alloantibody, of whom 18 had further than one alloantibody [10]. In the Netherlands, the frequencies of red cell alloantibodies detected in the first trimester was 1.2 %.[9]

Pathophysiology: -

There are two mechanisms causing hemolytic disorder of the fetus and infant. First, the fetomaternal match can have essential ABO incompatibility, which occurs in 15 to 25 of pregnancies. Only about 1 of those matches, those with high IgG twitters, will develop HDFN due to ABO incompatibility.[11] In ABO incompatibility, naturally being antigens against A or B blood types are present in mothers with O blood type. However, motherly anti-A and / or anti-B antibodies, individually, If the mother's fetus has an A or B (or AB) blood type. The anti-A and anti-B antibodies are IgG, which can cross the placenta and affect the developing fetus. [9] Compared with FMH, ABO incompatibility generally causes a less severe form of HDFN. Supposed propositions for this include fetal RBCs express lower ABO blood group antigens than adult situations and that ABO blood group antigens are expressed by numerous apkins, which reduces the chance that antibodies specifically target the antigens on fetal RBCs. [12]

The alternate medium most generally causing HDFN is through fetomaternal hemorrhage (FMH), where motherly antibodies develop after exposure to fetal blood. When fetal RBCs enter the motherly blood circulation, motherly antibodies can elaborate to an antigen carried on the fetal RBC surface. The most common antigen involved in this medium is the Rhesus D antigen. [13] Antigens in fetal blood that are foreign to motherly blood are inherited from paternal genes. For case, a Rh-negative woman can have a Rh-positive fetus due to her partner being Rh-positive. Antibodies that elaborate due to FMH put posterior pregnancies at danger for HDFN as the first antibodies to develop are of IgM type, which cannot cross the placenta. In posterior encounters with the Rh-D antigen, motherly antibodies quickly develop IgG antibodies, which serve cross the placenta [14].

After delivery, the unresistant blood group antibody can continue to affect neonatal red cells causing ongoing anemia until the motherly antibody is no longer present, which can be weeks to months after birth. In early neonatal anemia, bilirubin from red cell extinction can rise rapidly because the fetal liver metabolic organ isn't well developed. High degrees of unconjugated bilirubin can lead to bilirubin encephalopathy, which clinically presents acutely as languor, and can include neurological and muscular incorporations, similar as hypotonia, hypertonia, a weak suck, seizures, and / or coma, habitual and endless belongings of kernicterus, which is endless neuronal damage from hyperbilirubinemia, includes cerebral paralysis, audile dysfunction, intellectual, or other strikes.[9]

Signs and Symptoms: - The most common symptoms of HDN are -



Fig. 2 Symptoms of HDN

During gestation, it is achievable for symptoms to include:

• Mild anemia: When the child's red blood cell count is deficient, his blood cannot carry enough oxygen from the lungs to all region of his body, causing his organs and apkins to struggle.

• Hyperbilirubinemia and jaundice: The breakdown of red blood cells produces bilirubin, a brownish yellowish substance that is delicate for a baby to discharge and can raise up in his blood (hyperbilirubinemia) and make his skin appear yellowish.

• Severe anemia with expansion of the liver and spleen: The baby's body tries to compensate for the breakdown of red blood cells by making further of them very speedily in the liver and spleen, which causes the organs to get bigger. These new red blood cells are frequently immature and unfit to work comprehensively, leading to severe anemia.

• Hydrops fetalis: When the baby's body cannot manage with the anemia, his heart begins to fail and large quantities of fluid buildup in his apkins and organs.

After birth, possible symptoms include:

• Severe hyperbilirubinemia and jaundice: Inordinate buildup of bilirubin in the baby's blood causes his liver to come enlarged.

• Kernicterus: Buildup of bilirubin in the blood is so high that it spills over into the brain, which can lead to endless brain damage. [15]

Diagnosis: -

- Laboratory studies –

To diagnose and manage pregnant women with HDN, expansive laboratory and imaging practice is needed. HDN is clinically indicated by-

1. Rapid and severe hyper- bilirubinemia or patient hyperbilirubinemia
2. Hemolysis on blood film results. [16]

It should also be remarked that the extent of haematopoiesis affects the inflexibility of the diseases. [1]

Also, clinical conditions similar as anemia, thrombocytopenia, and neutropenia are frequently observed in cases. The anemia can be directly estimated using arteriole samples rather of capillary blood. Thrombocytopenia generally accompanies exchange transfusions. It results from poor blood platelets conformation and when the product is suppressed in favor of erythropoiesis. Neutropenia is mainly observed after intrauterine transfusion. It's generally associated with increased circulating cytokines (similar as granulocyte- macrophage colony- stimulating factor) and reticulocytosis, i.e., increased nucleated RBCs and cell fragmentation. [17,18]

In addition, Rh- HDN supplemental blood smears generally show polychromasia, anisocytosis, erythroblasts, and no spherocytes. [19]

likewise, a serological test requirement to be done to certify the positivity of the HDN. The results of this test may show that the baby is either directly or laterally impacted by the variation in the mother's Coombs and antibodies. According to a recent study, the positive impact of the natural antibody test finding is related to a prophetic value of 23 and a perceptivity of 86. [20] If the neonatal hemolytic cycle is caused by antic, the direct antibody test may be negative. As a result, it's suggested that a conclusion be made only when the circular Coombs test has shown certainty. Table 1 summarizes the laboratory tests employed in the conclusion of HDN and their anticipated results. [1]

Table No.1

Laboratory tests and Results for HDN-

Mother's sample Test	Result	Baby's sample Test	Result
ABO/Rh Determination	A (Rh D positive)	ABO/Rh Determination	A (Rh D positive)
Antibody Screening	Positive	Poly specific DAT	Positive
Antibody Identification	Anti-c testing	IgG/C3 Coombs	IgG positive/C 3d-negative
Antigen Typing	Negative for 'c' antigen	Elution	Positive

Note – Data from [1]

• *Imaging studies –*

Ultrasound- To determine organ expansion or fluid buildup in the fetus. Ultrasound is a distinct imaging method which uses high- frequence sound waves and a computer to produce images of blood vessels, apkins, and organs. Ultrasound is used to view

internal organs as they work, and to assess blood inflow through varied vessels. [21]

• *Laboratory tests after birth* –
Once a baby is born, typical tests for HDN may include the following –
• Testing of the baby's umbilical cord blood for blood group, Rh factor, red blood cell count, and antibodies.
• Testing of the baby's blood for bilirubin situations. [21]
To enhance health care results, a solid clinician-patient connection is needed. Collaboration among members of an interprofessional squad, which basically consists of an obstetrician, a primary physician, and nursers, is also demanded. Because this condition is avoidable, doctors must directly examine and screen both mother and father during the first trimester and nearly cover antibody titers in Rh- women. These antibody statuses should be lower than 1:16, and if they're advanced, invasive testing is performed to treat them correctly. Critical monitoring of the fetus using MCA Doppler provides an accurate picture of fetal anemia, determining if an intrauterine transfusion is needed or not. [22]

Treatment: -
Once HDN is diagnosed, treatment may be required. Specific treatment for hemolytic disorder of the infant will be determined by your baby's doctor predicated on:
• Your baby's prenatal age, overall health, and medical history
• Extent of the disorder
• Your baby's sufferance for specific medicines, procedures, or remedies
• prospects for the course of the disorder
• Your opinion or preference
During pregnancy, treatment for HDN may include:

• Intrauterine blood transfusion of red blood cells into the baby's rotation. This is done by placing a needle through the mother's uterus and into the abdominal hollow of the fetus or directly into the vein in the umbilical cord. It may be mandatory to give a tranquilizing drug to keep the baby from moving. Intrauterine transfusions may need to be repeated.
• Early delivery if the fetus develops complications. However, labor and delivery may be prevailed to help worsening of HDN, If the fetus has mature lungs. After birth, treatment may include.
• Blood transfusions (for severe anemia)
• Intravenous fluids (for low blood pressure)
• Help for respiratory pain using oxygen, surfactant, or a mechanical breathing machine
• Exchange transfusion to replace the baby's damaged blood with fresh blood. The exchange transfusion helps increase the red blood cell count and lower the positions of bilirubin. An exchange transfusion is done by alternating presenting and withdrawing blood in small quantities through a vein or artery. Exchange transfusions may need to be repeated if the bilirubin positions remain high. [21]
• Intravenous immunoglobin (IVIG). IVIG is a result made from blood plasma that contains antibodies to help the baby's vulnerable system. IVIG may help reduce the breakdown of red blood cells and lower bilirubin positions.
Adverse effects – Adverse effects can include headache, fever, nausea and rare serious responses like thrombosis or renal impairment. [23]

- Rh Immunoglobulin (RhIg) – RhIg, also known as Rhogam, an administered to Rh-negative pregnant women at specific times during pregnancy to prevent the formation of antibodies against Rh-positive blood cells.

RhIg is usually given around 28 weeks of pregnancy and within 72 hours after delivery or any event that may cause mixing of the mothers and baby's blood, such as a miscarriage or invasive prenatal testing.
Adverse effects – RhIg is generally well tolerated. Side effects are rare but can include local reaction at the injection such as pain, swelling or redness. [24]
• *Phototherapy* - Phototherapy is frequently used to treat hyperbilirubinemia, a common consequence of HDN, by converting bilirubin into a form that can be excreted more smoothly.

Adverse effects – Possible adverse effects of phototherapy include dehydration, skin rash, loose excreta. [25]

Prevention: -

Hemolytic disorder of the infant is preventable. Now, nearly all women with Rh-negative blood are identified in early pregnancy through blood tests. However, she's generally given a medicine called Rh immunoglobulin, or RhoGAM, if a mother is Rh-negative and has not been sensitized. This especially developed blood product prevents a Rh-negative mother's antibodies from responding to her baby's Rh-positive red blood cells. Mothers are generally given RhoGAM around the 28th week of gestation and again within 72 hours of giving birth. [15]

CONCLUSION

HDN is a complex multidimensional condition with unique specialized issues during multiple vital trial stages of the antenatal and neonatal eras. Advances in motherly- fetal drug, including the development of IVIG, IUT, and non-invasive fetal hereditary testing, have responded in significant enhancements in HDN conclusions and the avoidance of motherly allosensitization. Future advancements in blood typing and non-invasive testing will help women and their children with blood group incompatibility. Also, further attention should be given to the ethnical groups and races that are more at trouble.

REFERENCE

1. Myle, A. K., & Al-Khattabi, G. H. (2021). Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects. *Pediatric Health, Medicine and Therapeutics*, *Volume 12*, 491–498.https://doi.org/10.2147/phmt.s327032
2. Ah-Moye, D., Davies, C., Goody, J., Hayward, P., & Frewin, R. (2014). Introduction to haematology and transfusion science. In *Elsevier eBooks* (pp. 497–514). https://doi.org/10.1016/b978-0-7020-5140-1.00026-2
3. Aj, E. (2016). Hemolytic Disorders of the Newborn, Current Methods of Diagnosis and treatment: A review study. *HSOA Journal of Hematology, Blood Transfusion & Disorders*, *3*(1), 1–18. https://doi.org/10.24966/hbtd-2999/100008
4. Ree, I. M. C., Smits-Wintjens, V. E., Van Der Bom, J. G., Van Klink, J. M., Oepkes, D., & Lopriore, E. (2017). Neonatal management and outcome in alloimmune hemolytic disease. *Expert Review of Hematology*, *10*(7), 607–616. https://doi.org/10.1080/17474086.2017.1331124
5. *Hemolytic disease of the newborn: MedlinePlus Medical Encyclopedia*. (n.d.). https://medlineplus.gov/ency/article/001298.htm
6. Wang, R., Li, Y., Tong, Y., & N, S. (2020b). Hemolytic Disease of the Fetus and Newborn Caused by Anti-Group A IgG From a Group B Mother. *Journal of Pediatric Hematology Oncology*, *43*(6), e785–e787. https://doi.org/10.1097/mph.0000000000001948
7. Jl, N. (2001). On Dr. Louis K. Diamond's 1932 article and subsequent contributions to Erythroblastosis fetalis. *The American Journal of Pediatric Hematology/Oncology*, *23*(8), 550–553. https://doi.org/10.1097/00043426-200111000-00017
8. Basu, S., Kaur, R., & Kaur, G. (2011). Hemolytic disease of the fetus and newborn: Current trends and perspectives. *Asian Journal of Transfusion Science*, *5*(1), 3. https://doi.org/10.4103/0973-6247.75963
9. Delaney, M., & Matthews, D. C. (2015). Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. *Hematology*, *2015*(1), 146–151. https://doi.org/10.1182/asheducation-2015.1.146
10. Geifman-Holtzman, Ossie, et al. "Female alloimmunization with antibodies known to cause hemolytic disease." *Obstetrics & Gynecology* 89.2 (1997): 272-275.
11. Murray, N. A., & Roberts, I. (2007). Haemolytic disease of the newborn. *Archives of Disease in Childhood-fetal and Neonatal Edition*, *92*(2), F83–F88. https://doi.org/10.1136/adc.2005.076794
12. Metcalf, R. A., Khan, J., Andrews, J., Mayock, D. E., Billimoria, Z., & Pagano, M. B. (2019). Severe ABO hemolytic disease of the newborn requiring exchange transfusion. *Journal of Pediatric Hematology Oncology*, *41*(8), 632–634. https://doi.org/10.1097/mph.0000000000001248
13. Practice Bulletin No. 181: Prevention of RH D Alloimmunization. (2017). *Obstetrics & Gynecology*, *130*(2), e57–e70. https://doi.org/10.1097/aog.0000000000002232

14. Moinuddin, I., Fletcher, C. H., & Millward, P. (2019). Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan *Journal of Blood Medicine*, *Volume 10*, 283–289. https://doi.org/10.2147/jbm.s214118
15. *Hemolytic Disease | Boston Children's Hospital*. (n.d.). https://www.childrenshospital.org/conditions/hemolytic-disease
16. Koelewijn, J. M., Slootweg, Y. M., Folman, C. C., Van Kamp, I. L., Oepkes, D., & De Haas, M. (2019). Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non-D and non-K-alloimmunized pregnancies. *Transfusion*, *60*(2), 391–399. https://doi.org/10.1111/trf.15631
17. Mimura, K., Endo, M., Takahashi, A., Doi, Y., Sakuragi, M., Kiyokawa, T., Taniguchi, H., Kitabatake, Y., Handa, M., Tomimatsu, T., Tomiyama, Y., Isaka, Y., & Kimura, T. (2019). Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D−− phenotype. *International Journal of Hematology*, *111*(1), 149–154. https://doi.org/10.1007/s12185-019-02735-6
18. Slootweg, Y. M., Lindenburg, I. T., Koelewijn, J. M., Van Kamp, I. L., Oepkes, D., & De Haas, M. (2018). Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. *American Journal of Obstetrics and Gynecology*, *219*(4), 393.e1-393.e8. https://doi.org/10.1016/j.ajog.2018.07.020
19. Routray, S. S., Behera, R., Mallick, B., Acharya, D. P., Sahoo, J., Kanungo, G. N., & Pati, B. (2021). The spectrum of hemolytic disease of the newborn: Evaluating the etiology of unconjugated hyperbilirubinemia among neonates pertinent to immunohematological workup. *Cureus*. https://doi.org/10.7759/cureus.16940
20. Elalfy, M. S., Elbarbary, N. S., & Abaza, H. W. (2010). Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial. *European Journal of Pediatrics*, *170*(4), 461–467. https://doi.org/10.1007/s00431-010-1310-8
21. Philadelphia, C. H. O. (n.d.). *Hemolytic disease of the newborn*. Children's Hospital of Philadelphia. https://www.chop.edu/conditions-diseases/hemolytic-disease-newborn
22. Maisonneuve, E., Dugas, A., Friszer, S., Toly-Ndour, C., Cariot, L., Dhombres, F., Cortey, A., Mailloux, A., Carbonne, B., & Jouannic, J. (2021). Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: A case-control study. *Journal of Gynecology Obstetrics and Human Reproduction*, *50*(7), 102119. https://doi.org/10.1016/j.jogoh.2021.102119
23. Kim, Y. J., Dale, J. K., Noël, P., Brown, M. R., Nutman, T. B., Straus, S. E., & Klion, A. D. (2007). Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. *American Journal of Hematology*, *82*(7), 615–624. https://doi.org/10.1002/ajh.20851
24. Practice Bulletin No. 181: Prevention of RH D Alloimmunization. (2017b). *Obstetrics & Gynecology*, *130*(2), e57–e70. https://doi.org/10.1097/aog.0000000000002232
25. Hyperbilirubinemia, S. O. (2004c). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*, *114*(1), 297–316. https://doi.org/10.1542/peds.114.1.297